Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation
Mélissa Prat(Université Toulouse III - Paul Sabatier), Agnès Coste(Centre National de la Recherche Scientifique)
Cited by 9
Related Papers
No related papers found
Powered by citation graph analysis